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Introduction: Schizophrenia is a disorder that produces considerable burdens due to its often 
relapsing/remitting or chronic longitudinal course. This burden is felt not only by patients them-
selves, but also by their families and health care systems. Although the societal burden caused 
by this disorder has been evaluated in several countries, the magnitude of the societal cost of 
schizophrenia in Japan has never been estimated. The aim of this study is to clarify the societal 
burden of schizophrenia by estimating the cost of schizophrenia in Japan in 2008.
Methods: A human capital approach was adopted to estimate the cost of schizophrenia. The 
total cost of schizophrenia was calculated as the sum of the direct, morbidity, and mortality costs. 
Schizophrenia was defined as disorders coded as F20.0–F20.9 according to the International 
Classification of Diseases-10. The data required to estimate the total cost was collected from 
publicly available statistics or previously reported studies.
Results: The total cost of schizophrenia in Japan in 2008 was JPY 2.77 trillion (USD 23.8 billion). 
While the direct cost was JPY 0.770 trillion (USD 6.59 billion), the morbidity and mortality 
costs were JPY 1.85 trillion (USD 15.8 billion) and JPY 0.155 trillion (USD 1.33 billion), 
respectively.
Conclusion: The societal burden caused by schizophrenia is tremendous in Japan, similar to 
that in other developed countries where published data exist. Compared with other disorders, 
such as depression or anxiety disorders, the direct cost accounted for a relatively high propor-
tion of the total cost. Furthermore, absolute costs arising from unemployment were larger, 
while the prevalence rate was smaller, than the corresponding results for depression or anxiety 
in Japan.
Keywords: cost of illness, schizophrenia, societal burden, cost analysis, societal cost
Introduction
Schizophrenia causes a considerable burden not only for patients themselves, but also 
for families who must provide care and for social care systems. Several reasons have 
been proposed to explain the magnitude of the societal cost of this disorder, includ-
ing the high probability of disease relapse and the high incidence of chronic features. 
According to a report by Crown et al,1 40% to 60% of patients with schizophrenia 
suffer from life-long impairment arising from this illness. These factors can reduce 
social function, and can lead to long-term hospitalization, increasing morbidity cost, 
and consumption of health care resources. The Global Burden of Disease Study reported 
that 0.4% of the total disability adjusted life years across all diseases could be attributed 
to schizophrenia in 1990, and this figure had increased to 0.6% by 2010.2
Schizophrenia has been recognized as the most expensive disorder among all 
psychiatric disorders in terms of health care expenditure per patient.3 The overall rates 
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of national health expenditure for schizophrenia in the late 
1980s and 1990s were 1.5% in the UK;4 2% in the Nether-
lands,5 France,6 and Belgium;7 and 2.5% in the USA.8 
Due to the rapidly aging population and the increased 
cost associated with advances in health technology, the 
importance of the efficient use and reasonable allocation of 
scarce health care resources has become more crucial than 
ever before in the context of Japanese health policy devel-
opment. Estimating the societal burden of each illness and 
clarifying what effective and efficient interventions can be 
performed should be viewed as consecutive steps for achiev-
ing this process. With respect to schizophrenia, a much larger 
number of people with schizophrenia (ie, the patients of the 
post-World War II baby-boom generation) are also surviving 
into old age. In an inpatient-dominated mental health system, 
associated costs could rise even more. Therefore, the efficient 
use of scarce resources becomes more important. Several 
studies have already been conducted to estimate the social 
burden caused by schizophrenia in the UK, US, and other 
countries.9–13 A study examining the societal burden caused 
by depression in Japan14 has also been reported, but there are 
no published studies on the societal burden of schizophrenia 
in Japan, to the authors’ knowledge.
Objective
The objective of this study was to evaluate the cost of schizo-
phrenia in Japan in 2008 from a societal perspective.
Methods
A prevalence-based approach was adopted to measure the 
total cost of schizophrenia among adults (20 years of age 
or more) in Japan in 2008. 2008 data were used as 2008 
is the most recent year for which all necessary data were 
available. Schizophrenia is defined as disorders coded as 
F20.0–F20.9 in International Classification of Diseases 
(ICD)-10. A broader definition of schizophrenia such as 
that used in the Global Burden of Disease Study2 would 
be F20.0–F29 in ICD-10. However, using such a broad 
definition would include other psychotic disorders such as 
schizoaffective disorder and acute and transient psychotic 
disorders. To avoid overinclusivity we judged it appropriate 
to adopt the earlier definition.
The costs included in the analysis were direct cost, 
morbidity cost, and mortality cost. The informal care costs, 
which are defined as the costs of care provided by nonpro-
fessional caregivers such as family, friends, acquaintances, 
or neighbors of a patient, for which they do not have to be 
financially compensated,15 were excluded because no reliable 
data are available to estimate this cost in Japan.
This study was conducted from a societal perspective. 
Data were collected from publicly available statistics and 
reports. We acknowledged the possibility that data derived 
from these statistics varied depending on the year surveyed 
because the data were estimated by random sampling. 
Therefore, where previous data were available,16,17 data 
were checked and confirmed to be stable. Analyses were 
conducted according to conservative principles (ie, the 
avoidance of overestimates). The results are shown both 
in Japanese Yen (JPY) and US dollars (USD). Purchasing 
power parity between JPY and USD in 2008 (USD 1 = JPY 
116.8) was used to calculate the USD equivalent of each 
cost component.
Direct costs
The health care costs covered by health insurance
To calculate the health care costs covered by health insur-
ance, we mainly used two Ministry of Health, Labour and 
Welfare data sources: the Patient Survey16 and the Survey 
of Medical Care Activities in Public Health Insurance.17 In 
Japan, universal health care is provided under public health 
insurance schemes. The volume of services provided under 
these schemes is reported annually by the Survey of Medi-
cal Care Activities in Public Health Insurance,17 while the 
number of the patients, categorized by diagnosis, utilizing 
health care services within these schemes is estimated every 
3 years by the Patient Survey.16
Direct cost 28%
Morbidity cost 67%
Mortality cost 5%
Figure 1 Proportion of each cost component.
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Outpatient costs
Outpatient cost data were gathered from Patient Survey16 
and the Survey of Medical Care Activities in Public Health 
Insurance.17 The Patient Survey reports were used to estimate 
the number of patients in each diagnostic category for all 
physical and mental diseases, while the Survey of Medical 
Care Activities in Public Health Insurance was used to obtain 
the total treatment expenses for all treatments covered by 
public health insurance for each diagnostic category for a 
period of 1 month.
Regarding schizophrenia, the Survey of Medical Care 
Activities in Public Health Insurance17 only reported the 
total combined outpatient costs for all psychotic disorders 
(ie, F20.0–F29: F2 group), aggregating costs associated 
with schizophrenia and schizoaffective disorder, etc. The 
costs specifically associated with schizophrenia were not 
reported  separately. In order to account for this, the propor-
tion of patients with schizophrenia among all the patients in 
the F2 group was estimated from the Patient Survey16 to cal-
culate the cost specifically attributable to schizophrenia, under 
the assumption that the average outpatient cost among patients 
with different psychotic disorders was the same. The following 
formula was used to calculate the annual outpatient costs:
 (1)
where C
sch-out
 is the outpatient cost of schizophrenia, C
f2-out
 is 
the outpatient cost of the F2 group, N
sch-out
 is the estimated 
number of the outpatients with schizophrenia, and N
f2-out
 
is the estimated number of the outpatients with F2 group 
diagnoses.
Inpatient costs
Data on the cost of inpatient treatment was also obtained from 
the Patient Survey16 and the Survey of Medical Care Activities 
in Public Health Insurance.17 Similar to the reported outpatient 
costs above, only the total cost of the F2 group per month was 
available; consequently, the rate of schizophrenia among the 
F2 group in the Patient Survey was determined and used to 
calculate the inpatient treatment cost for schizophrenia. No 
difference was assumed to exist among the average treatment 
costs for the different disorders in the F2 group.
The formula calculating annual outpatient cost is as 
below:
 C C
N
Nsch in f in
sch in
f in
- -
-
-
= 2
2
× × 12, (2)
where C
sch-in
 is the inpatient cost of schizophrenia, C
f2-in
 is the 
inpatient cost of the F2 group, N
sch-in
 is the estimated number 
of inpatients with schizophrenia, and N
f2-in
 is the estimated 
number of inpatients with F2 group diagnoses.
Medication costs
Only antipsychotics were included in previous studies calcu-
lating the medication costs for the treatment of schizophrenia. 
However, antipsychotics are also provided for patients with 
other psychiatric disorders. On the other hand, other medica-
tions, such as mood stabilizers, antidepressants, and anxiolytic 
drugs, are prescribed for many patients with schizophrenia. 
To resolve this problem, we estimated the medication costs 
for schizophrenia as the cost of all prescribed drugs, both 
psychotropic and non-psychotropic, for patients diagnosed 
as having schizophrenia, such as antidepressants, mood sta-
bilizers, anxiolytic drugs, and antihypertensives.
While the Survey of Medical Care Activities in Public 
Health Insurance17 provided the total medication costs of the 
F2 group both for inpatients and outpatients, it did not provide 
the specific total costs for schizophrenia. The total medica-
tion cost for schizophrenia was calculated by multiplying the 
net costs for the F2 group by the proportion of patients with 
schizophrenia among the patients in the F2 group.
The formulae for calculating inpatient and outpatient 
medication costs are as follows:
 C C
N
Nsch in m f in m
sch in
f in
- - - -
-
-
= 2
2
× × 12  (3)
and
 C C
N
Nsch out m f out m
sch out
f out
- - - -
-
-
= 2
2
× × 12,  (4)
where C
sch-in-m
 and C
sch-out-m
 are the inpatient and outpatient 
medication costs of schizophrenia, C
f2-in-m
 and C
f2-out-m
 are the 
inpatient and outpatient medication costs of the F2 group, 
N
sch-in
 and N
sch-out
 are the estimated numbers of inpatients 
and outpatients with schizophrenia, and N
f2-in
 and N
f2-out
 are 
the estimated numbers of inpatients and outpatients with 
F2 group diagnoses. Medication costs covered by Japan’s 
Diagnosis Procedure Combination/per-diem payment system 
were excluded from the inpatient medication costs calculated 
above, as these costs are already included in the inpatient cost 
of schizophrenia calculated in the previous section.
Involuntary admission costs
In Japan, there are two distinct types of formal admission: 
“medical protection admission” and “involuntary admission.” 
C C
N
Nsch out f out
sch out
f out
-
-= 2
2
× × 12,
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Therefore, a patient can be admitted to hospital in three ways 
in Japan: (1) voluntary admission to which the patient con-
sents; (2) medical protection admission, when a psychiatrist 
designated by law, specifically, the Law Related to Mental 
Health and Welfare of the Person with Mental Disorder,18 
judges that a patient has mental disorder, requires inpatient 
treatment, and is not consenting, but a guardian of the patient 
agrees to the admission and treatment; or (3) involuntary 
admission, when two independent, designated psychiatrists’ 
assessments conclude that a patient has a mental illness and 
presents a risk to themself or others.
The Law Related to Mental Health and Welfare of the 
Person with Mental Disorder, is described by the Law Society 
thusly:
To provide person(s) with mental disorder with medical 
care and protection, and in combination with the purpose of 
this Law is to Support Independence of Disabled Persons to 
offer necessary assistance for promoting their social reha-
bilitation, self-support, and participation in socio-economic 
activities, and to endeavor to prevent onset thereof, main-
tain, and promote mental health of the people in general, 
to thereby advance general well-being of the person(s) 
with mental disorder and to enhance mental health of the 
people in general.19
Under the arrangement for voluntary admissions and 
medical protection admissions, costs are met by health insur-
ers in the usual way and so costs are captured in inpatient 
admission costs as described above. However, involuntary 
admission costs are met by a separate budget directly funded 
by the tax-payer and so need to be added to the stated inpa-
tient costs above.
Involuntary admission costs were estimated by multi-
plying the point estimate of the total number of patients 
with schizophrenia admitted involuntarily by the average 
daily inpatient cost and by 365 days. The point estimate of 
the total number of patients with schizophrenia admitted 
involuntarily was derived from a Mental Health and Welfare 
document20 published in 2007. The average daily inpatient 
cost was assumed to be the same as that of the inpatient 
cost under the health insurance schemes. The average daily 
inpatient cost under the health insurance schemes was esti-
mated from the Survey of Medical Care Activities in Public 
Health Insurance.17 The proportion of patients with schizo-
phrenia admitted involuntarily among all the involuntarily 
admitted patients was calculated as follows. First, the total 
number of involuntarily admitted patients was multiplied 
by the rate of F2 group patients among all the involuntarily 
 admitted patients. Then, the result was multiplied by the ratio 
of patients with schizophrenia among the F2 group patients 
derived from the Patient Survey16 and the Survey of Medical 
Care Activities in Public Health Insurance.17
Costs of provision under the Medical Care  
and Supervision Act in Japan
The Medical Care and Supervision Act in Japan defines 
the provision of appropriate medical care and treatment 
in order to promote social rehabilitation for persons who 
have committed serious crimes under the condition of 
insanity or diminished capability.21 The budget for the 
execution of mental health supervision and the execution 
of medical care provision under the Medical Care and 
Supervision Act in Japan was used as the starting point 
for calculating the cost of provision under the Medical 
Care and Supervision Act in Japan. The rate of patients 
with schizophrenia among all the patients treated under 
the Medical Care and Supervision Act in Japan was not 
available but was calculated by hypothesizing that the rate 
of the number of F2 group patients among all psychiatric 
patients and the rate of the number of patients with schizo-
phrenia among all the F2 group patients under the Medical 
Care and Supervision Act in Japan would be the same as 
the rate of the number of F2 group patients among all the 
psychiatric patients admitted involuntarily20 and the rate 
of the number of patients with schizophrenia among all 
the F2 group patients under the health insurance schemes 
from the Patient Survey16, respectively.
Social service costs
The cost of all services provided under the Services and 
Supports for Persons with Disabilities Act was regarded as 
the total social service costs. As described by the Ministry 
of Health, Labour and Welfare, this Act aims to improve the 
welfare of persons (adults) and children with disabilities 
through the provision of benefits for necessary disability 
welfare services and provision of other forms of support to 
enable persons (adults) and children with disabilities to live 
independent daily or social lives according to their respective 
abilities and aptitudes.22 The costs of other social services 
provided outside the scope of this act, such as the medical 
assistance costs covered by public assistance (ie, financial 
support for medical treatment costs by local government 
for those under public assistance), and the costs for health 
centers and group homes, should have been included in this 
cost; however, these components had to be excluded from 
the analysis because of the lack of available data.
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The data regarding service use related to the Services and 
Supports for Persons with Disabilities Act was derived from 
a Mental Health and Welfare document20 and a study titled 
“Survey of patients with mental disorders attending mental 
health clinics who are not involved in social activities cur-
rently, and research to improve the support of patients wishing 
to become involved in social activities (Asukuri research)” 
conducted by the Japanese Association of Mental Health 
Services in 2007.23 The Mental Health and Welfare docu-
ment20 reported the total number of patients using outpatient 
services provided by the Services and Supports for Persons 
with Disabilities Act, such as a support office for continuous 
employment (type A), a support office for continuous employ-
ment (type B), a transition support office for employment, and 
a rehabilitation service office, all irrespective of psychiatric 
diagnosis. Consequently, the specific number of patients with 
schizophrenia utilizing these services was unclear.
The Asukuri research23 provided data on the community 
services described above under the Services and Supports 
for Persons with Disabilities Act for psychiatric patients 
attending 113 clinics in December 2007, stratified according 
to diagnosis. The research clarified the ratio of patients with 
schizophrenia among all the patients using these services. 
This allowed the total number of patients with schizophrenia 
per year who utilized services provided by the Services and 
Supports for Persons with Disabilities Act from the Mental 
Health and Welfare document20 to be estimated by multi-
plying the total number of patients who accessed services 
provided by the Services and Supports for Persons with Dis-
abilities Act by the ratio of patients with schizophrenia among 
all the patients included in the Asukuri research. The cost of 
the Services and Supports for Persons with Disabilities Act 
was calculated by multiplying this total number of patients 
with schizophrenia by the average daily cost (JPY 4261: 
USD 36.5) for services under the Services and Supports for 
Persons with Disabilities Act.
Indirect costs
Indirect costs are comprised of morbidity and mortality costs. 
Morbidity costs occur when patients are not able to function 
normally as a result of their illness,24 while mortality costs 
arise when patients die as a result of suicide at an age earlier 
than the average life expectancy.
Morbidity costs
Morbidity costs reflect the productivity loss caused by 
absence from work (ie, absenteeism) and productiv-
ity loss while at work (ie, presenteeism) and that due to 
unemployment (ie, unemployment costs). Larg and Moss25 
proposed components such as absenteeism, presenteeism, 
unemployment, premature death, treatment-related time off 
work, unwanted job changes, loss of opportunities for pro-
motion and education, and loss of unpaid production while 
ill as potential production losses (ie, morbidity and mortal-
ity costs). However, no reliable data in Japan are available 
with regard to absenteeism, presenteeism, treatment-related 
time off work, unwanted job changes, loss of opportunities 
for promotion and education, and loss of unpaid production 
while ill, so these costs were omitted from the analysis and 
only the unemployment costs were reflected in the morbidity 
costs. Although the components we were able to include in the 
morbidity costs were limited, we note this problem has con-
fronted other authors, and previous studies10,26 have included 
only unemployment or unemployment and absenteeism as 
morbidity costs as well. In the analysis we assumed that the 
gap between the employment rate of the general population 
and that of patients with schizophrenia was a result of the 
illness, and the costs caused by this gap were included in the 
analysis as unemployment costs.
The sex/age-specific unemployment cost was calculated 
by multiplying the sex/age-specific number of patients with 
schizophrenia by the sex/age-specific employment rate dif-
ferences between the general population and patients with 
schizophrenia, and the average yearly earning using the 
following formula:
 UC = Po × Pr × (E
gen
 - E
schi
) × W, (5)
where UC is the unemployment cost, Po is the population 
size, Pr is the point prevalence of schizophrenia, E
gen
 is 
the employment rate of the general population, E
schi
 is the 
employment rate of patients with schizophrenia, and W is the 
average yearly earning. The total unemployment cost was 
estimated by summating each category of sex/age-specific 
unemployment costs.
The employment rate of the general population and that 
of patients with schizophrenia were derived from the Labour 
Force Survey27 and the Asukuri research,23 respectively.
The prevalence rate should be derived from general popula-
tion samples, rather than samples of patients accessing health 
care, because some individuals with schizophrenia do not 
access health care. We conducted a literature review to obtain 
a precise sex/age-specific prevalence rate for Japan. Saha et al28 
conducted a systematic review regarding the prevalence of 
schizophrenia in the general population that included studies 
performed in Japan.29–34 However, the subjects of these articles 
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Table 1 Prevalence and the number of the patients with 
schizophrenia
Age Population  
(thousand)a
Prevalenceb Number of patients 
(thousand)
Male
20–24 3650 0.004 13
25–29 3892 0.005 18
30–34 4565 0.007 33
35–39 4858 0.009 42
40–44 4236 0.009 40
45–49 3906 0.011 43
50–54 3904 0.011 41
55–59 4865 0.010 51
60–64 4374 0.009 39
65–69 3845 0.007 26
70– 8199 0.004 34
Total 50,294 380
Female
20–24 3455 0.004 15
25–29 3738 0.006 22
30–34 4430 0.007 29
35–39 4750 0.007 32
40–44 4170 0.009 37
45–49 3875 0.009 35
50–54 3918 0.010 39
55–59 4972 0.010 48
60–64 4584 0.009 43
65–69 4195 0.008 35
70– 11,977 0.006 69
Total 54,064 404
Notes: aDerived from Vital Statistics;35 bcalculated based on data from Vital 
Statistics35 and the Patient Survey.16
were elderly people, college students, or patients receiving 
treatment, rather than the general  population. Consequently, we 
felt that these results were probably not representative of Japan 
overall. Because of the lack of such data, we assumed that 
only those subjects who accessed treatment could be regarded 
as suffering from schizophrenia in Japan and calculated the 
12-month prevalence by dividing the sex/age-specific number 
of patients with schizophrenia accessing treatment by that of 
the general population.35 The total number of patients under 
treatment was obtained from the Patient Survey.16 Although the 
Patient Survey is based on a 1-day survey, the total number of 
patients under treatment represents all patients receiving treat-
ment irrespective of having a treatment on the date surveyed 
or not by calculating using the formula below:
 Nt = Ni + N
fv
 + N
rv
 × D × (6/7), (6)
where Nt is the total number of patients under treatment, 
Ni is the number of inpatients, N
fv
 is the number of first-
visit outpatients, N
rv
 is the number of outpatients under 
follow up, and D is the average duration between follow 
up appointments.
The prevalence rate obtained through this procedure was 
the point prevalence, rather than the 12-month prevalence. In 
general, however, the morbidity period of schizophrenia is 
relatively long. Consequently, we assumed that the discrep-
ancy between the point prevalence and that of the 12-month 
prevalence was minimal and regarded the point prevalence 
as being equivalent to the 12-month prevalence. The details 
are shown in Table 1.
The sex/age-specific employment rates of patients with 
schizophrenia were provided by the Asukuri research.23 
In the data provided, schizophrenia was not differentiated 
from other illness coded as belonging to the F2 group. 
 Consequently, the employment rate of the F2 group is 
regarded as being the same as that of the patients with 
schizophrenia. Finally, the sex/age-specific average yearly 
earnings were calculated from the Basic Survey on Wage 
Structure.36 All the parameters and their distributions used 
for calculating morbidity costs are shown in Table 2.
Mortality costs
The definition of mortality cost was the net present value 
(NPV) of the expected lifetime earnings loss caused by 
suicides because of schizophrenia. It was calculated by 
multiplying the estimated number of suicides arising from 
schizophrenia by the NPV of the expected lifetime earnings. 
The NPV was calculated using the formula below:
 NPV
E W
iq
n n
n q
n q
= ⋅
=
∑
( )
,
1
1
+
 (7)
where q is the age at the time of death by suicide, n is the age 
of the patients if they had survived, l is the life expectancy, 
E
n
 is the employment rate at the age of n, W
n
 is the average 
yearly earning at the age of n, and i is the discount rate.
The total number of suicides was obtained from the Statis-
tics of Suicide.37 The ratio of suicide caused by schizophrenia 
was obtained from a report by Kaga.38 The reason that this ratio 
was chosen was that although the sample size was relatively 
small (n = 76), a psychological autopsy had been conducted 
for 76 of the suicides, and the demographic data of the sample 
was representative of the data for all suicide cases in Japan.
The Basic Survey on Wage Structure36 and the Labour Force 
Survey27 were referenced to estimate the lifetime  earnings. 
The discounting rate was set at 3%, as this rate has been used 
in recent international studies.39 All the parameters and their 
distributions included in the model to calculate the mortality 
cost are shown in Table 3.
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Uncertainty
We collected the best evidence available when performing the 
analyses. However, some uncertainty regarding the parameters 
remains. The nature of the available data was responsible for 
this limitation. Accordingly, in order to ensure the robustness 
of the estimated cost of schizophrenia, probabilistic sensitiv-
ity analyses (PSA)40,41 were conducted to calculate the mean 
morbidity and mortality costs and their standard errors (SEs). 
The probability distributions around the input variables were 
based on the SEs quoted in or calculated from previous reports. 
We used the PSA function in Excel 2007 (Microsoft Corpora-
tion, Redmond, WA, USA) for this, which is basically a macro 
allowing multiple recalculations of Excel spreadsheet data 
using a different value from the uncertainty distribution defined 
for the input variables. We calculated the mean values and their 
SEs for the output variables from amongst 5000 values that 
were generated in this manner. The results were then presented 
to three significant digits together with their SEs.
Results
Direct costs
The direct costs of schizophrenia in Japan in 2008 were 
estimated to be JPY 770 billion (USD 6.59 billion). The 
health care costs covered by health insurance were JPY 
751 billion (USD 6.43 billion). The involuntary admission 
costs were JPY 6.18 billion (USD 53 million), the cost of 
the Medical Care and Supervision Act in Japan was JPY 
9.54 billion (USD 82 million), and the social service costs 
were JPY 3.48 billion (USD 30 million). The outpatient and 
inpatient costs were JPY 148 billion (USD 1.27 billion) and 
JPY 603 billion (USD 5.16 billion), respectively (including 
medication costs). The details are shown in Tables 4 and 5.
Indirect cost
Morbidity cost (unemployment cost)
The point prevalences, stratified according to sex and age, 
ranged from 0.4%–1.1%, as indicated in Table 1. The employ-
ment rates for individuals aged 25 to 59 years were 89% to 
94% for men and 60% to 73% for women in the general 
population, while those for patients with schizophrenia were 
15% to 31% for men and 4% to 29% for women (Table 2). By 
multiplying the differences in the employment rates between 
the general population and the patients with schizophrenia 
by the expected yearly earning, the lost employment costs 
were calculated. Because the employment rate of the patients 
with schizophrenia used in the calculation contained some 
 uncertainty, the mean and the SE of the unemployment 
costs were calculated by conducting a PSA to reflect this 
 uncertainty in the results. As a result, the mean unemploy-
ment cost was JPY 1.85 trillion (USD 15.8 billion) and its 
SE was JPY 706 million (USD 6 million) (Table 6).
Mortality cost
The total number of suicides in Japan in 2008 was 31,638. 
The number of suicides stratified according to sex and 
age is shown in Table 3. The ratio of suicides attributed to 
schizophrenia among all the suicides was cited from Kaga 
(ie, 0.095).38 The mortality costs were estimated by multiply-
ing the sex/age-specific number of suicides among patients 
with schizophrenia by the sex/age-specific expected lifetime 
Table 3 Parameters for calculation of the mortality cost
Age Number  
of suicidesa
Distribution Expected lifetime  
earning (JPY: thousand)b
Distribution Rate of suicides caused  
by schizophrenia (SE)c
Distribution
Male
20–29 2373 Deterministic 121,766 Deterministic 0.095 (0.034) Beta
30–39 3396 Deterministic 119,104 Deterministic 0.095 (0.034) Beta
40–49 3852 Deterministic 94,737 Deterministic 0.095 (0.034) Beta
50–59 4986 Deterministic 52,633 Deterministic 0.095 (0.034) Beta
60+ 7639 Deterministic 11,489 Deterministic 0.095 (0.034) Beta
Unkown 204 Deterministic 63,317 Deterministic 0.095 (0.034) Beta
Female
20–29 1065 Deterministic 57,818 Deterministic 0.095 (0.034) Beta
30–39 1454 Deterministic 50,972 Deterministic 0.095 (0.034) Beta
40–49 1118 Deterministic 38,805 Deterministic 0.095 (0.034) Beta
50–59 1377 Deterministic 20,822 Deterministic 0.095 (0.034) Beta
60+ 4154 Deterministic 4704 Deterministic 0.095 (0.034) Beta
Unkown 20 Deterministic 24,791 Deterministic 0.095 (0.034) Beta
Notes: aDerived from Statistics of Suicides in 2008;37 bderived from Basic Survey on Wage Structure;36 cderived from Kaga.38
Abbreviation: SE, standard error.
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earnings. Because the ratio of suicides attributed to schizo-
phrenia among all the suicides was somewhat uncertain, 
a PSA was performed to clarify the mean cost and its SE. 
The mean mortality cost and its SE were JPY 155 billion 
(USD 1.33 billion) and JPY 783 million (USD 7 million), 
respectively (Table 6).
Discussion
To our knowledge, this is the first study to evaluate the soci-
etal cost of schizophrenia in Japan. The results showed that 
the total cost of schizophrenia was JPY 2.77 trillion (USD 
23.7 billion) and the indirect costs constituted the great-
est part of the total cost (72% of the total cost) (Table 7) 
(Figure 1). Of note, previous studies also reported that the 
indirect costs accounted for a major part of the total costs 
(71% in the US in1991;12 52% in the US in 2002;11 52% in 
the UK in 2004/200510). However, international comparisons 
of the costs of schizophrenia are quite difficult to make, 
not only because health and social care systems differ sig-
nificantly internationally, but also because the methodology 
of each study varies considerably. Therefore, considerable 
caution should be exercised when comparing the results in 
this study with those in other countries. Particularly, there 
is too much uncertainty around estimates of indirect costs 
to allow meaningful comparison. However, less uncertainly 
exists in estimates of direct costs, and so here we focus on 
comparing only a subset of specific elements of the direct 
costs of schizophrenia between countries in which health 
care expenditure against gross domestic product is similar in 
order to draw some preliminary conclusions. We would like 
to make some cautious comparisons using a study reporting 
English data by Mangalore and Knapp.10
Because the number of psychiatric beds per capita in 
Japan is approximately four times greater than that in the 
UK,42 many of those who reside in other facilities outside 
hospitals such as care homes and group homes in England 
are likely to reside in a hospital in Japan. To account for this 
difference, it is more appropriate to compare health care costs 
in the study reported above with health and social care, and 
institutional costs in aggregate reported by Mangalore and 
Knapp for England.10
Mangalore and Knapp indicate that health and social care, 
and institutional costs in England are approximately GBP 
1.79 billion.10 Considering the population size (128 million 
in Japan,35 53 million in England43) and currency exchange 
rate (GBP 1 = JPY 183: purchasing power parity),42 this 
figure would be equivalent to JPY 0.789 trillion of direct 
costs of schizophrenia for Japan, implying that differences 
in direct costs between the two countries are surprisingly 
small. Furthermore, inpatient costs constituted 80% of the 
total health care costs (including the involuntary admission 
costs) in Japan in this study (Table 4), while in England the 
comparable figure would be 77%, suggesting limited differ-
ences in costs of institutional care for schizophrenia. Given 
the major differences between the UK and Japan in how care 
for schizophrenia is organized and delivered (inpatient versus 
community), the drugs available to treat schizophrenia, and 
the rates of comorbidity with illicit drug use, these differences 
are surprisingly small.
Comparing the cost of schizophrenia to other mental 
disorders in Japan, a report published in 201145 estimated 
the costs of depression and anxiety disorders in 2008 using 
the same methodology. This 2011 report and the result of our 
study reported here, when taken together indicate that for all 
three of these mental disorders the indirect costs accounted 
for the greater part of the societal cost (72% in schizo-
phrenia; 91% in depression; and 98% in anxiety  disorders). 
Further, the proportion of each component in the making up 
of the indirect costs among these three disorders would appear 
Table 4 Inpatient and outpatient costs
Total costs (JPY: million)
Health care costs under health insurance
 Inpatient costs 602,771
 Outpatient costs 148,047
Involuntary admission costs* 6184
Note: *Involuntary admission is classified into inpatient cost.
Table 5 Direct costs
Point estimate
(JPY: million)
Health care cost 766,545
 Health care care cost under health insurance schema 750,818
 Involuntary admission cost 6184
 The medical care and supervision act cost 9543
Social service cost 3477
Total direct cost 770,022
Table 6 Morbidity and mortality cost
Mean (JPY: million)
SE
Morbidity cost 1,849,651 706
 Unemployment cost 1,849,651 706
Mortality cost 154,708 783
Total indirect cost 2,004,359 1067
Abbreviation: SE, standard error.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
795
The cost of schizophrenia in Japan
Neuropsychiatric Disease and Treatment 2013:9
to reflect the characteristics of each disorder. In schizophrenia, 
the costs imposed by unemployment constituted the largest 
component, accounting for about 92%, while in depression and 
anxiety disorders, absenteeism and presenteeims is the biggest 
part of the indirect cost (53% in depression and 59% in anxiety 
disorders). Absenteeism and presenteeism were not included as 
cost components in our estimation of the cost of schizophrenia. 
However, considering the low employment rate and the low 
prevalence rate of patients with schizophrenia compared to 
those with depression or anxiety disorders (both approximately 
one third of the employment rate and prevalence rate of depres-
sion based on Sado et al),45 even if the cost of these components 
were estimated, it would not have had a great influence on the 
composition of the indirect costs. (An approximate estimate 
of the absenteeism and presenteeism costs in schizophrenia 
might be JPY 170 billion [USD 1.46 billion]; less than 10% 
of the unemployment cost of schizophrenia).
These findings indicates that, in schizophrenia, the 
greater part of the indirect costs occurred outside of the 
workplace (ie, unemployment costs), while in depression 
and anxiety disorders, the cost inside the workplace (ie, 
absenteeism and presenteeism) constituted the largest 
component. Based on these findings, to reduce the societal 
burden caused by schizophrenia, future research should 
focus more on how to improve employment rather than an 
intervention for absenteeism and presenteeism. In order to 
achieve this, more attention should be paid to improvement 
not only of the symptoms of schizophrenia but also to the 
social function of patients.
Limitations
Although we were able to include a variety of the societal 
costs of schizophrenia in this study, there remain some costs 
that we were unable to include. For example, some costs such 
as the medical assistant costs covered by public assistance, 
a large part of social service costs, informal care costs, and 
the costs of absenteeism/presenteeism were not analyzed in 
this study because of the lack of available data. In particular, 
with regard to social service costs, although ideally a variety 
of services such as health centers and group homes should 
have been included, only the costs directly associated with 
the Services and Supports for Persons with Disability Act 
were analyzed because it was not possible to obtain data 
about the extent to which these other costs were attributable 
specifically to schizophrenia. Consequently, the burden of 
schizophrenia will have been underestimated. Furthermore, 
the fact that the data utilized in the analyses were derived 
from a variety of sources is another limitation. Data for 2008, 
or the closest year available, were used. When data with a 
broad sampling was impossible to obtain, smaller samplings 
were used. Although such limitations are inevitable in this 
type of study, they may have increased the uncertainty of 
the present results. These limitations should be taken into 
consideration when interpreting the present results. To assess 
the burden more fully, data related to informal care and 
productivity loss at work will be crucial in future studies. 
Furthermore, precise data regarding the employment rates 
and the suicide rate of patients with schizophrenia could 
improve the accuracy of the results.
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